Y. R. Kimbung

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

D. Logan, S. Dillon, M. Maurer, 2022, Nature Communications.

Crystal structures of the Chromobacterium violaceumω‐transaminase reveal major structural rearrangements upon binding of coenzyme PLP

D. Logan, Per Berglund, B. Walse, 2012, The FEBS journal.

New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.

C. Pál, T. Révész, Ž. Skok, 2021, European journal of medicinal chemistry.